Original Article
Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo
N Engl J Med 1993; 328:914-921April 1, 1993
- Abstract
Background
Characteristics such as age and race are often cited as determinants of the response of blood pressure to specific antihypertensive agents, but this clinically important issue has not been examined in sufficiently large trials, involving all standard treatments, to determine the effect of such factors.
Methods
In a randomized, double-blind study at 15 clinics, we assigned 1292 men with diastolic blood pressures of 95 to 109 mm Hg, after a placebo washout period, to receive placebo or one of six drugs: hydrochlorothiazide (12.5 to 50 mg per day), atenolol (25 to 100 mg per day), captopril (25 to 100 mg per day), clonidine (0.2 to 0.6 mg per day), a sustained-release preparation of diltiazem (120 to 360 mg per day), or prazosin (4 to 20 mg per day). The drug doses were titrated to a goal of less than 90 mm Hg for maximal diastolic pressure, and the patients continued to receive therapy for at least one year.
Results
The mean (±SD) age of the randomized patients was 59 ±10 years, and 48 percent were black. The average blood pressure at base line was 152 ±14/99 ±3 mm Hg. Diltiazem therapy had the highest rate of success: 59 percent of the treated patients had reached the blood-pressure goal at the end of the titration phase and had a diastolic blood pressure of less than 95 mm Hg at one year. Atenolol was successful by this definition in 51 percent of the patients, clonidine in 50 percent, hydrochlorothiazide in 46 percent, captopril in 42 percent, and prazosin in 42 percent; all these agents were superior to placebo (success rate, 25 percent). Diltiazem ranked first for younger blacks (<60 years) and older blacks ( ≥ 60 years), among whom the success rate was 64 percent, captopril for younger whites (success rate, 55 percent), and atenolol for older whites (68 percent). Drug intolerance was more frequent with clonidine (14 percent) and prazosin (12 percent) than with the other drugs.
Conclusions
Among men, race and age have an important effect on the response to single-drug therapy for hypertension. In addition to cost and quality of life, these factors should be considered in the initial choice of a drug.
Media in This Article
Figure 1
Patients with a Diastolic Blood Pressure of Less Than 90 mm Hg or a Systolic Blood Pressure of Less Than 140 mm Hg at the End of the Titration Phase.Figure 2
Patients with Responses in Each of the Study Groups.Article Activity
- Article
The initial treatment for hypertension has changed as drugs with pharmacologic properties permitting single-drug therapy have become available. In their 1988 report, the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure1 considered the selection of initial treatment on the basis of demographic characteristics.
Previous cooperative studies by the Department of Veterans Affairs have supported the recommendations of the Joint National Committee, such as proposing that beta-blockers be considered equal to thiazide diuretics in the initial antihypertensive therapy of white patients2,3 and recommending the use of captopril as initial single-drug therapy4,5. We and others have also observed differential racial responses to antihypertensive drugs2-8. Speculation that demographic characteristics would predict clinically important differences in the antihypertensive efficacy of various drugs and permit better selection of single-drug therapy has not been substantiated by a placebo-controlled, prospective randomized trial of representative drugs from each of the major therapeutic classes.
We studied different classes of antihypertensive drugs used as single-drug therapy. Our primary objectives were to determine the efficacy of each drug in lowering blood pressure, the ability to control blood pressure over time, and the incidence of termination of treatment for medical reasons. We also compared short-term efficacy and long-term control in the various drug classes according to age and race. Neither cost nor quality-of-life issues were studied.
Methods
Study Design and Selection of Patients
Male veterans being evaluated as outpatients entered a washout phase lasting from four to eight weeks before randomization, during which they received one placebo tablet twice daily administered in a single-blind fashion. The criteria for inclusion were an age of 21 years or older, written informed consent, and a reasonable expectation that the patient's diastolic blood pressure would be between 95 and 109 mm Hg with placebo. Patients were excluded from the study if they had any of a number of medical conditions listed elsewhere (NAPS). Each patient underwent routine laboratory testing and electrocardiography. Interviews to gather information on side effects were conducted at the second visit and each subsequent visit.
The base-line blood pressure was calculated as the average of the readings obtained at the last two clinic visits in the period before randomization. Compliance was determined on the basis of the patient's clinic attendance and a count of pills. Patients were randomized if their mean diastolic blood pressure on two consecutive visits was between 95 and 109 mm Hg and if the values did not differ by more than 6 mm Hg between visits.
At the time of randomization, the patients were assigned in a double-blind manner7 to receive placebo or one of the six study drugs. They then entered a titration phase of four to eight weeks. The drugs and their doses (listed from low to medium to high) were hydrochlorothiazide (12.5, 25, and 50 mg daily), atenolol (25, 50, and 100 mg daily), clonidine (0.2, 0.4, and 0.6 mg in divided doses given twice daily), captopril (25, 50, and 100 mg in divided doses given twice daily), prazosin (4, 10, and 20 mg in divided doses given twice daily), a sustained-release preparation of diltiazem (120, 240, and 360 mg in divided doses given twice daily), and placebo. Prazosin was started at 1 mg given twice daily for two days to minimize the risk of hypotension with the first dose. All medications were started at the lowest dose, and the dose was increased every two weeks, as required, until a diastolic blood pressure of less than 90 mm Hg was reached without intolerance to the drug on two consecutive visits or until the maximal drug dose was reached. The blood pressure during treatment was taken as the mean of the blood pressures recorded during the last two visits during the titration phase.
Patients whose diastolic blood pressure had reached the goal (a reading of less than 90 mm Hg) on two consecutive visits during the titration phase entered a maintenance phase for at least one year. During this period, interim visits were permitted in order to adjust the dose of drug as needed to maintain the diastolic blood pressure at 99 mm Hg or less and to reduce adverse effects. Control was defined as a diastolic blood pressure of less than 95 mm Hg at one year. Success was defined as attainment of the blood-pressure goal during titration and the maintenance of controlled blood pressure for one year.
After the maintenance phase, each patient entered a four-week placebo washout phase. Patients who had been randomly assigned to clonidine therapy had their doses tapered down over a two-week period to avoid withdrawal symptoms.
The protocol was approved by an institutional review board at each of the 15 participating medical centers and by a central human-studies committee.
Measurement of Blood Pressure
Trained registered nurses or physicians' assistants used standard sphygmomanometers with appropriately sized cuffs to determine blood pressure. The patients were seated with an arm supported at the level of the heart after five minutes of rest. The disappearance of the Korotkoff sounds defined the diastolic blood pressure. The mean of three readings taken one minute apart was used as the blood pressure at that clinic visit.
Adverse Drug Reactions and Termination of Treatment
A 31-item checklist was used to inquire about the patients' symptoms. The patients were encouraged to describe their symptoms at each visit. All withdrawals from the study protocol were evaluated blindly by the study chairman and classified as administrative or medical. Medical withdrawals were further analyzed blindly to determine whether they were due to an adverse drug reaction.
Statistical Analysis
The primary outcome measure was the rate of treatment success (the percentage of randomized patients who reached the blood-pressure goal during the titration phase and maintained control of blood pressure for one year). The rate at which the goal for blood pressure was achieved during the titration phase and the rate of termination due to adverse reactions were secondary outcome measures. The significance of each outcome measure was determined by a chi-square test of homogeneity for a two-by-seven contingency table.
All results are reported according to an intention-to-treat analysis. SAS software9 was used for all analyses. Chi-square tests of homogeneity10 were performed to compare the proportions for all categorical responses in the seven treatment groups, whereas analysis of variance was used to compare the means for all continuous responses in these groups. When the results were significant at P ≤ 0.05, differences between pairs of treatments were tested with pairwise contrasts for proportions or Tukey's procedure for means10. In these analyses, it is inappropriate to report individual P values for each of the 15 possible pairwise comparisons. Instead, a P value of 0.05 was selected for each group of 15 pairwise comparisons and used to identify the subgroups of treatment pairs that were significantly different. All P values were two-tailed.
Results
Characteristics of the Patients
We randomly assigned 1292 patients to the seven treatment groups. Their base-line characteristics (Table 1Table 1
Characteristics of the Randomized Patients as a Whole and According to Age and Race.) were well balanced across the seven treatment groups. The mean (±SD) age of the 546 younger patients (those less than 60 years old) was 50 ±8 years, and for the 746 older patients (those 60 years old or older) it was 66 ±4 years. A total of 137 patients withdrew from the study during the titration period, and 410 patients did not qualify for the maintenance phase; the remaining 745 patients entered the maintenance phase. Of these, 145 withdrew from the study during the first year of the maintenance phase, and 65 withdrew thereafter; 535 entered the final placebo period. Thus, 41 percent of the patients initially randomized completed the study.Blood-Pressure Response during the Titration Phase
During the titration phase, there were significant (P<0.001) differences between treatments in the mean decrements in diastolic and systolic blood pressure (Table 2Table 2
Average Reductions in Blood Pressure from Base Line to the End of the Titration Phase.), the proportion of patients reaching the goal for diastolic blood pressure (<90 mm Hg), and the proportion of patients with systolic blood pressure below 140 mm Hg.The pairwise comparisons indicated that the mean decrement in diastolic blood pressure was greater with diltiazem than with all the other active drugs except clonidine; clonidine and atenolol were more effective than captopril. The proportion of patients reaching the goal for diastolic pressure was higher with diltiazem than with hydrochlorothiazide, prazosin, or captopril; patients taking clonidine or atenolol reached this goal at a rate similar to that of patients taking the other drugs (Figure 1Figure 1
Patients with a Diastolic Blood Pressure of Less Than 90 mm Hg or a Systolic Blood Pressure of Less Than 140 mm Hg at the End of the Titration Phase.). In the case of systolic pressure, the proportion of patients with readings below 140 mm Hg was higher with clonidine and hydrochlorothiazide than with prazosin, captopril, or placebo (Figure 1). The effects of diltiazem and atenolol were not significantly different from those of the other active agents. The effects of prazosin and captopril were not significantly different from those of placebo.The response profile for each dosage of medication during the titration phase (Table 3Table 3
Responses to Treatment at the End of the Titration Phase and Withdrawals at Each Dose Level during the Titration and Maintenance Phases.) showed that a high proportion of patients with a response reached the goal for that phase at the lowest dosage: 12.5 mg of hydrochlorothiazide once a day (45 percent), 25 mg of atenolol once a day (49 percent), 0.1 mg of clonidine twice a day (48 percent), and 2 mg of prazosin twice a day (48 percent). The group assigned to diltiazem had the highest proportion of responses, but many of these patients required the higher dosage.Blood-Pressure Response during the Maintenance Phase
The 745 patients who reached the goal for diastolic blood pressure without intolerable side effects entered a maintenance phase of at least one year and continued to receive blinded therapy. During this phase there were small increases in systolic and diastolic blood pressure (4 ±11 and 2 ±6 mm Hg, respectively). The percentage of patients with initial control of blood pressure in whom the diastolic blood pressure remained below 95 mm Hg at one year was similar for all treatment groups (P = 0.926), ranging from 82 percent (for hydrochlorothiazide) to 75 percent (for prazosin).
For the primary study end point, the proportion of patients initially randomized who responded to therapy and maintained a diastolic pressure below 95 mm Hg after one year of treatment, there were significant (P<0.001) differences between treatments (Figure 2Figure 2
Patients with Responses in Each of the Study Groups.). This rate of treatment success reflects the initial blood-pressure response, the number of patients who did not withdraw because of side effects or other causes, and the degree to which control was maintained. The pairwise comparisons show that diltiazem was more effective than captopril or prazosin. All the treatments were superior to placebo.Blood-Pressure Response According to Age and Race
Race and, to a somewhat lesser extent, age were powerful influences on the response of blood pressure to individual drugs. Data obtained at the end of the titration phase (Table 2) indicate statistically significant differences between drugs. Figure 3Figure 3
Younger Black Patients, Younger White Patients, Older Black Patients, and Older White Patients with Responses in Each of the Study Groups. shows the criterion of a 15 percent difference in efficacy between two or more drugs, the difference specified in the study design to be clinically important.There were no statistically significant differences according to age and race with respect to mean changes in either systolic or diastolic blood pressure from base line to the end of the titration phase (Table 2). Blood pressure was reduced by 11 ±10/10 ±7 mm Hg for 243 younger whites, by 9 ±11/9 ±8 mm Hg for 288 younger blacks, by 12 ±12/12 ±6 mm Hg for 405 older whites, and by 11 ±12/11 ±7 mm Hg for 330 older blacks. There were significant differences between drugs according to age and race. Clonidine, atenolol, and diltiazem were the most effective in reducing the diastolic blood pressure of younger whites; hydrochlorothiazide was the least effective. Diltiazem was most effective for younger blacks, and prazosin least effective. All the drugs were similarly effective for older whites; diltiazem was most effective for older blacks, and captopril least effective.
Rates of treatment success were different for the different drugs in each of the four groups defined according to age and race (Figure 3). Younger black patients responded best to diltiazem; older blacks to diltiazem or hydrochlorothiazide; younger whites to captopril, atenolol, or clonidine; and older whites to atenolol, diltiazem, captopril, clonidine, hydrochlorothiazide, or prazosin (listed in descending order).
Final Placebo Phase
At the end of the final placebo phase, the diastolic blood pressure remained at least 6 mm Hg below the base-line level in all the treatment groups except the clonidine group, in which it returned to 1 mm Hg below the base-line value. In the case of systolic blood pressure, all treatment groups except the clonidine group had values at least 1 mm Hg below base line after the final placebo phase, but the values for the clonidine group were 8 mm Hg above base line. Similar results were obtained for the difference between the final visit in the maintenance phase and that in the final phase: blood pressure increased by 22/13 mm Hg after the withdrawal of clonidine, a larger increase than was found with any other drug. The pairwise comparisons showed that clonidine was significantly different in this regard from all other drugs and placebo.
Adverse Drug Effects
During the titration phase, there were significant differences between groups in the percentage of patients requiring withdrawal from the study drug or a reduction in dosage because of side effects. Patients treated with clonidine or prazosin were intolerant of the study drug more often (14 and 12 percent of the respective treatment groups) than patients given captopril (7 percent), placebo (6 percent), atenolol (5 percent), diltiazem (4 percent), or hydrochlorothiazide (3 percent).
Only patients receiving clonidine or prazosin had significantly more side effects during the titration phase than patients receiving placebo. In the case of the clonidine group, these side effects were fatigue (17 percent of patients vs. 8 percent for placebo), sleepiness (30 percent vs. 6 percent), nonpostural dizziness (8 percent vs. 5 percent), and dry mouth (37 percent vs. 6 percent). In the case of the prazosin group, the side effects were fatigue (13 percent of patients vs. 8 percent for placebo), sleepiness (12 percent vs. 6 percent), and nonpostural dizziness (12 percent vs. 5 percent). No drug was associated with a significant increase in the frequency of impotence or edema.
Termination of Treatment
Of the 1292 randomized patients, 137 (10.6 percent) were withdrawn from the trial during the titration phase (Table 3). Of the 745 patients who entered the maintenance phase, 145 (19.5 percent) were withdrawn within one year. In the case of 194 patients treatment was terminated for medical reasons, including loss of blood-pressure control in 44 patients and adverse drug reactions in 84 (Table 3). Most adverse drug reactions were those known to be associated with the specific drugs. In the placebo group, they included dizziness (three patients), sleep disturbances (two patients), severe dry mouth, acute gout, and proteinuria (one patient each). There was one termination of treatment due to proteinuria in each drug group except the clonidine group. Three patients died during the study from causes unrelated to the study drug.
Prazosin had the highest rate of adverse effects leading to the termination of treatment (13.8 percent), which was significantly higher than the rate for captopril (4.8 percent), atenolol (2.2 percent), or hydrochlorothiazide (1.1 percent). The rate for clonidine (10.1 percent) was significantly different from the rates for hydrochlorothiazide and atenolol. The rate for diltiazem was 6.5 percent, and for placebo 6.4 percent.
There were no significant differences between drug groups with respect to the rates of adverse effects that caused the termination of treatment among younger blacks (0 to 6.8 percent). Among younger whites, the comparison of prazosin (15.2 percent) with both hydrochlorothiazide (2.9 percent) and captopril (2.6 percent) approached statistical significance. Among older whites, the rates for prazosin (19.0 percent) and clonidine (16.7 percent) were higher than the rates for atenolol (1.7 percent) and hydrochlorothiazide (1.7 percent). The rates for the other three treatment groups ranged from 5.7 to 9.1 percent. For older blacks, the comparison of both diltiazem (12.2 percent) and prazosin (11.3 percent) with placebo (0 percent) approached statistical significance.
Laboratory Data
In the hydrochlorothiazide-treated patients, pairwise comparisons showed that the increase in serum cholesterol of 3.3 mg per deciliter (0.086 mmol per liter) was significantly different from the decrease of 9.3 mg per deciliter (0.24 mmol per liter) in the prazosin group, but was not different from the changes in the placebo group or the other groups, and it did not persist at one year. Fasting blood glucose increased significantly by 6.7 mg per deciliter (0.37 mmol per liter) in the hydrochlorothiazide group as compared with the placebo, captopril, and atenolol groups, and it remained elevated at two years.
Discussion
Although it was limited to male veterans, this study provides new information about the comparative efficacy of six commonly used drugs for the initial therapy of mild-to-moderately-severe hypertension. The inclusion of a placebo group allowed a true estimate of the active drug effects, and the large study population -- nearly 200 patients per treatment group -- provided adequate power to detect differences between drugs. Furthermore, the population was large and heterogeneous enough for differences in treatment responses to be examined according to age and race. Our conclusions about the comparative efficacy of the six study drugs are influenced by the doses selected. Different results might have been obtained if different doses had been chosen.
This study differed from other comparative studies of single-drug therapy for hypertension8,11,12 in that it prospectively compared representatives of six classes of drugs with each other and with placebo. A sufficient number of patients were randomly assigned to the drug groups for valid conclusions to be drawn from the data.
We demonstrated that the response to single-drug therapy in this group of hypertensive patients was quite high, although there were significant differences among drugs in achieving that response. The blood-pressure decrement achieved by placebo (3 mm Hg systolic and 5 mm Hg diastolic) and the response rate are similar to those of previous studies. Overall, the most consistent response of diastolic blood pressure was to diltiazem. There were no significant differences in the response rates of white patients to the various drugs, although atenolol and captopril had the highest response rates at one year. Systolic blood pressure was most responsive to hydrochlorothiazide and clonidine. Captopril was the least effective in black patients, a subgroup in whom angiotensin-converting-enzyme inhibitors and beta-blockers are known to be less effective. However, the magnitude of the change in blood pressure, the percentage of patients who reached the goal for blood pressure, and the 58 percent response rate at one year for white patients are all consistent with the results of our previous study of captopril4. Furthermore, in the present study captopril ranked first in younger whites and third (after atenolol and diltiazem) in older whites. In general, prazosin was less effective than the other drugs; it and clonidine were the least well tolerated of the six.
The mechanisms underlying the varying responses among the classes of agents remain unclear. It has been proposed that blacks and older patients may be less responsive to angiotensin-converting-enzyme inhibitors and more responsive to diuretics and calcium-channel blockers because these groups of patients tend to have low-renin hypertension13,14. Although the current data are consistent with these hypotheses, they do not establish a mechanism for this pattern of responses. In any case, in several demographic groups the differences between drugs are substantial enough to guide the initial choice of a drug.
Few studies have evaluated more than two antihypertensive agents prospectively in placebo-controlled trials. The Treatment of Mild Hypertension Study11 was a randomized, parallel, placebo-controlled study of antihypertensive agents similar to those used in our trial. All the patients participated in a diet for weight and sodium reduction and a program of increased physical activity that reduced blood pressure by 10.6/8.1 mm Hg. No differences in efficacy were observed among drugs.
The Trial of Antihypertensive Interventions and Management12 tested various diets plus antihypertensive drug therapy with either chlorthalidone or atenolol. Black patients responded better to chlorthalidone plus dietary sodium restriction, whereas white patients responded better to atenolol plus diet. Saunders and collaborators8 studied atenolol, captopril, and sustained-release verapamil in 394 black patients. They observed short-term decreases in diastolic blood pressure similar to those in our study.
Diuretics (both hydrochlorothiazide and chlorthalidone) have had impressive efficacy in treating isolated systolic hypertension in the elderly15-17. Our study did not include subjects with isolated systolic hypertension, but hydrochlorothiazide was somewhat more effective in reducing systolic blood pressure in older patients of both races. Three cooperative studies by the Department of Veterans Affairs showed that thiazide diuretics were more effective in older patients than in younger ones and had a greater effect on the reduction of systolic pressure in the older patients18.
Low-dose hydrochlorothiazide (12.5 mg per day) and atenolol (25 mg per day) produced significant responses; 12.5 mg of hydrochlorothiazide was associated with only minimal biochemical perturbations. Hydrochlorothiazide-treated patients in this study had the lowest rate of drug intolerance and the fewest terminations of treatment for adverse drug reactions, but hydrochlorothiazide was less effective in younger patients. Conversely, although diltiazem was highly effective, a high proportion of patients had adequate blood-pressure control only at the highest dose. The doses of captopril employed in this study were those usually used in clinical practice. It is not known whether the use of a higher or more frequent dose would have improved the results with this drug, although other studies have shown the dose-response curve to be flat from 75 to 150 mg4,5,19.
The subjects in this study were not characteristic of the general population with hypertension. They were older and more likely to be black, and there were no women. We are not aware of valid data that demonstrate a meaningful difference in drug response according to sex20. Nevertheless, we cannot generalize our results to women. Our study does not pertain to important factors, such as the effect of racial identity and socioeconomic status in the causation or prevalence of hypertension,21 nor do we address specific mechanisms of hypertension. We believe that our data do demonstrate the power of the patient's race and age as determinants of the response to various antihypertensive drugs and that racial identification is important for that specific purpose.
Antihypertensive treatment must be tailored to the individual patient. Small differences in efficacy may be less important than differences in quality of life or cost. This study provides some guidelines for the practicing physician about which drugs to try initially to control patients' blood pressure, taking into consideration the characteristics of the patient. When they are subsequently combined with data on costs and quality of life, the results of this study may clarify recommendations on the preferred single-drug therapy for specific groups of patients. A long-term study that includes women is needed to identify the possible advantages of one or more of these classes of drugs in reducing morbidity and mortality from cardiovascular causes.
Presented in part at the American Heart Association Scientific Sessions, Anaheim, Calif., November 11, 1991.
Supported by the Cooperative Studies Program of the Department of Veterans Affairs Medical Research Service and by an unrestricted grant to Friends of Medical Research, Inc. (a not-for-profit foundation), from Marion Merrell Dow, Inc.
NAPS See NAPS document no. 05006 for 5 pages of supplementary material. To order, contact NAPS c/o Microfiche Publications, 248 Hempstead Tpk., West Hempstead, NY 11552.
We are indebted to the following companies for supplying us with study drugs and matching placebos: Ciba-Geigy (for providing hydrochlorothiazide), ICI Pharma (atenolol), Bristol-Myers Squibb (captopril), Boehringer-Ingelheim Pharmaceuticals (clonidine), Marion Merrell Dow (diltiazem), and Pfizer Laboratories Division (prazosin).
Source Information
From the Cooperative Studies Program of the Medical Research Service, Department of Veterans Affairs.
Address reprint requests to Dr. Materson at the Veterans Affairs Medical Center (141), 1201 NW 16th St., Miami, FL 33125.
The members of the study group are listed in the Appendix.
Appendix
The members of the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents were as follows: Miami -- B.J. Materson (chairman), R.A. Preston, J. Asch, M.H. Smith, and C. Rainey; Hines, Ill. -- W.G. Henderson, D.J. Reda (biostatistician), J. Rowe, S. Tir, R. Mais, B. Lizano, D. Koontz, and B. Mackay; Albuquerque, N.M. -- M.R. Sather, C. Fye (pharmacist), S. Buchanan, C. Foy, and F. Chacon; Washington, D.β -- E.D. Freis, I. Khatri, B. Gregory, J. Gottdiener, A. Notargiacomo, R. Lakshman, R. Sapp, and P. Coutlakis; San Juan, P.R. -- E.A. Ramirez, J.L. Cianchini, and A. Jimenez; Boston -- R.J. Hamburger, M. Tobin, and A. Pieczek; Allen Park, Mich. -- F.N. Talmers and C. Grant; Dallas -- W.W. Neal and M. Henry; East Orange, N.J. -- K.C. Mezey and B. Luzniak; Houston -- R.E. Borreson and C. Stewart; Jackson, Miss. -- N.T. Srivastava and K.M. Cooper; New York -- L.A. Katz and R. Mannix; Memphis, Tenn. -- W.C. Cushman, S. Nunn, and A. McKnight; Milwaukee -- M.S. Kochar, D. Trottier, and P. Olzinski; St. Louis -- H.M. Perry, Jr., D. Berg, L. Monahan, and J. Politte; San Francisco -- B. Massie, J. Tubau, and E. Der; and Topeka, Kans. -- B. Mukherji, M. Pannone, C. Arnold, and K. Fox.
Data Monitoring Board: W.M. Kirkendall (chairman) (deceased), University of Texas Medical School, Houston; W.H. Gaasch, Worcester Memorial Hospital, Worcester, Mass.; R.W. Gifford, Jr., Cleveland Clinic Foundation, Cleveland; and R.F. Woolson, University of Iowa College of Medicine, Iowa City. Veterans Affairs Central Office: D. Deykin (chief, Cooperative Studies Program), P. Huang, and J. Gold, Boston and Washington, D.C.
- References
References
1
The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure
CrossRef | Web of Science | Medline2
Veterans Administration Cooperative Study Group on Antihypertensive Agents
CrossRef | Web of Science3
Veterans Administration Cooperative Study Group on Antihypertensive Agents
CrossRef | Web of Science4
Veterans Administration Cooperative Study Group on Antihypertensive Agents
CrossRef | Web of Science | Medline5
Veterans Administration Cooperative Study Group on Antihypertensive Agents 6
Veterans Administration Cooperative Study Group on Antihypertensive Agents
Web of Science | Medline7
Materson BJ ,Cushman WC ,Goldstein G , et al. Treatment of hypertension in the elderly. I. Blood pressure and clinical changes: results of a Department of Veterans Affairs cooperative study. Hypertension 1990;15:348-360
Web of Science | Medline8
Saunders E ,Weir MR ,Kong BW , et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-1713
CrossRef | Web of Science | Medline9
SAS/STAT user's guide, version 6. 4th ed. Vols. 1, 2. Cary, N.C.: SAS Institute, 1989.
10
Woolson RF. Statistical methods for the analysis of biomedical data. New York: John Wiley, 1987.
11
The Treatment of Mild Hypertension Research Group
CrossRef | Web of Science | Medline12
Wassertheil-Smoller S ,Oberman A ,Blaufox MD ,Davis B ,Langford H . The Trial of Antihypertensive Interventions and Management (TAIM) study: final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992;5:37-44
Web of Science | Medline13
Cody RJ ,Laragh JH ,Case DB ,Atlas SA . Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension 1983;5:Suppl III:III-3614
Freis ED ,Materson BJ ,Flamenbaum W . Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. Am J Med 1983;74:1029-1041
CrossRef | Web of Science | Medline15
SHEP Cooperative Research Group
CrossRef | Web of Science16
Amery A ,Birkenhager W ,Brixko R , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet 1986;2:589-592
CrossRef | Web of Science | Medline17
Cushman WC ,Khatri I ,Materson BJ , et al. Treatment of hypertension in the elderly. III. Response of isolated systolic hypertension to various doses of hydrochlorothiazide: results of a Department of Veterans Affairs cooperative study. Arch Intern Med 1991;151:1954-1960
CrossRef | Web of Science | Medline18
Freis ED . Age and antihypertensive drugs (hydrochlorothiazide, bendroflumethiazide, nadolol and captopril). Am J Cardiol 1988;61:117-121
CrossRef | Web of Science | Medline19
Drayer JIM ,Weber MA . Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension 1983;5:Suppl III:III-10820
Medical Research Council Working Party
CrossRef | Web of Science | Medline21
Osborne NG ,Feit MD . The use of race in medical research. JAMA 1992;267:275-279
CrossRef | Web of Science | Medline
- Citing Articles (327)
Citing Articles
1
Vivencio Barrios. (2011) Diltiazem in the treatment of hypertension and ischemic heart disease. Expert Review of Cardiovascular Therapy 9:11, 1375-1382
CrossRef2
John H. Laragh, Jean E. Sealey. (2011) The Plasma Renin Test Reveals the Contribution of Body Sodium-Volume Content (V) and Renin–Angiotensin (R) Vasoconstriction to Long-Term Blood Pressure. American Journal of Hypertension 24:11, 1164-1180
CrossRef3
Angela Brown, Becky Captain. (2011) 50 Years of Thiazides: Should Thiazide Diuretics Be Considered Third-Line Hypertension Treatment?. American Journal of Therapeutics 18:6, e244-e254
CrossRef4
Domenic A. Sica, Barry Carter, William Cushman, Lee Hamm. (2011) Thiazide and Loop Diuretics. The Journal of Clinical Hypertension 13:9, 639-643
CrossRef5
Markos Karavitakis, Christos Komninos, Pavlos N. Theodorakis, Vasilios Politis, Georgios Lefakis, Kostas Mitsios, Sotirios Koritsiadis, Grigorios Doumanis. (2011) Evaluation of Sexual Function in Hypertensive Men Receiving Treatment: A Review of Current Guidelines Recommendation. The Journal of Sexual Medicine 8:9, 2405-2414
CrossRef6
Chin-Chou Huang, Chia-Min Chung, Shuen-Iu Hung, Hsin-Bang Leu, Tao-Cheng Wu, Po-Hsun Huang, Shing-Jong Lin, Wen-Harn Pan, Jaw-Wen Chen. (2011) Genetic variation in renin predicts the effects of thiazide diuretics. European Journal of Clinical Investigation 41:8, 828-835
CrossRef7
Joel Handler. (2011) Managing Erectile Dysfunction in Hypertensive Patients. The Journal of Clinical Hypertension 13:6, 450-454
CrossRef8
Jason Lee, Hossein Aziz, Lin Liu, Michael Lipkowitz, Daniel T. O'Connor, Erin Richard, Victoria Brophy, Christina L. Wassel, Roland Blantz, Vibha Bhatnagar. (2011) β1-Adrenergic Receptor Polymorphisms and Response to β-Blockade in the African-American Study of Kidney Disease and Hypertension (AASK). American Journal of Hypertension 24:6, 694-700
CrossRef9
D. Richter, C. Mickel, S. Acharya, P. Brunel, C. Militaru. (2011) Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control. International Journal of Clinical Practice 65:5, 613-623
CrossRef10
John M. Flack, Samar A. Nasser, Phillip D. Levy. (2011) Therapy of Hypertension in African Americans. American Journal Cardiovascular Drugs 11:2, 83-92
CrossRef11
Haroon Kamran, Louis Salciccioli, Carl Bastien, Patricia Castro, Abhishek Sharma, Jason M. Lazar. (2011) Effect of beta blockers on central aortic pressure in African-Americans. Journal of the American Society of Hypertension 5:2, 94-101
CrossRef12
Jason T. Davis, Maple M. Fung. (2011) Ethnicity and Second-Line Antihypertensive Medication Response in the ASCOT Trial. Current Hypertension Reports 13:1, 8-10
CrossRef13
Endang Susalit, Nafrialdi Agus, Imam Effendi, Raymond R. Tjandrawinata, Dwi Nofiarny, Tania Perrinjaquet-Moccetti, Marian Verbruggen. (2011) Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: Comparison with Captopril. Phytomedicine 18:4, 251-258
CrossRef14
Maximilian T. Lobmeyer, Liewei Wang, Issam Zineh, Stephen T. Turner, John G. Gums, Arlene B. Chapman, Rhonda M. Cooper-DeHoff, Amber L. Beitelshees, Kent R. Bailey, Eric Boerwinkle, Carl J. Pepine, Julie A. Johnson. (2011) Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenetics and Genomics 21:1, 42-49
CrossRef15
Ning Chen, Mi Yang, Li He, Dongping Zhang, Muke Zhou, Cairong Zhu, Li He. 2010. Corticosteroids for preventing postherpetic neuralgia. .
CrossRef16
Joseph E. Biskupiak, Jaewhan Kim, Hemant Phatak, David Wu. (2010) Prevalence of High-Risk Cardiovascular Conditions and the Status of Hypertension Management Among Hypertensive Adults 65 Years and Older in the United States: Analysis of a Primary Care Electronic Medical Records Database. The Journal of Clinical Hypertension 12:12, 935-944
CrossRef17
M H Weinberger, R D Glazer, N A Crikelair, Y T Chiang. (2010) Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy. Journal of Human Hypertension 24:12, 823-830
CrossRef18
Alan H. Gradman. (2010) Rationale for Triple-Combination Therapy for Management of High Blood Pressure. The Journal of Clinical Hypertension 12:11, 869-878
CrossRef19
Ajay K. Gupta, Neil R. Poulter, Joanna Dobson, Sandra Eldridge, Francesco P. Cappuccio, Mark Caulfield, David Collier, J. Kennedy Cruickshank, Peter S. Sever, Gene Feder. (2010) Ethnic Differences in Blood Pressure Response to First and Second-Line Antihypertensive Therapies in Patients Randomized in the ASCOT Trial. American Journal of Hypertension 23:9, 1023-1030
CrossRef20
Stephen T. Turner, Gary L. Schwartz, Arlene B. Chapman, Amber L. Beitelshees, John G. Gums, Rhonda M. Cooper-DeHoff, Eric Boerwinkle, Julie A. Johnson, Kent R. Bailey. (2010) Plasma Renin Activity Predicts Blood Pressure Responses to β-Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for Hypertension. American Journal of Hypertension 23:9, 1014-1022
CrossRef21
Roberto Fogari, Stefano Taddei, Merete Holm-Bentzen, Jacek Baszak, Lorenzo Melani, Kai Schumacher. (2010) Efficacy and Safety of Olmesartan Medoxomil 40 mg/Hydrochlorothiazide 12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Moderate to Severe Hypertension. Clinical Drug Investigation 30:9, 581-597
CrossRef22
Michael H. Alderman, Hillel W. Cohen, Jean E. Sealey, John H. Laragh. (2010) Pressor Responses to Antihypertensive Drug Types. American Journal of Hypertension 23:9, 1031-1037
CrossRef23
Morris J. Brown. (2010) Heterogeneity of Blood Pressure Response to Therapy. American Journal of Hypertension 23:9, 926-928
CrossRef24
Yan Lv, Zui Zou, Guan-min Chen, Huai-Xin Jia, Jing Zhong, Wei-Wu Fang. (2010) Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Pressure Monitoring 15:4, 195-204
CrossRef25
Serap Erdine, Eren Arslan. (2010) Patient adherence in the treatment of hypertension: the role of combination therapies. Future Cardiology 6:4, 437-440
CrossRef26
Lesley-Ann Miller, Rolin Wade, Dingwei Dai, Mark J. Cziraky, Krishnan Ramaswamy, Sumeet Panjabi. (2010) Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension. Current Medical Research and Opinion 26:6, 1307-1320
CrossRef27
Martin C. S. Wong, Johnny Y. Jiang, Xuefen Su, Haoxiang Wang, Jin Ling Tang, Sian M. Griffiths. (2010) Individuals at risk of beta-blocker discontinuation: a cohort study in 19,177 Chinese patients. Clinical Research in Cardiology 99:5, 277-284
CrossRef28
Domenic A. Sica. (2010) The Evolution of Renin-Angiotensin Blockade: Angiotensin-Converting Enzyme Inhibitors as the Starting Point. Current Hypertension Reports 12:2, 67-73
CrossRef29
Justin W. Timbie, Rodney A. Hayward, Sandeep Vijan. (2010) Diminishing Efficacy of Combination Therapy, Response-Heterogeneity, and Treatment Intolerance Limit the Attainability of Tight Risk Factor Control in Patients with Diabetes. Health Services Research 45:2, 437-456
CrossRef30
MD Montgomery, DB Bylund. (2010) Lack of effect of the α2C-adrenoceptor Del322-325 polymorphism on inhibition of cyclic AMP production in HEK293 cells. British Journal of Pharmacology 159:4, 820-830
CrossRef31
O M Dekkers, E v. Elm, A Algra, J A Romijn, J P Vandenbroucke. (2010) How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology 39:1, 89-94
CrossRef32
José Antonio GarcÃa-Donaire, Luis Miguel Ruilope. (2010) âMultiple action fixed combination. Present or future?â. Fundamental & Clinical Pharmacology 24:1, 37-42
CrossRef33
Jenny MH Chen, Balraj S Heran, Marco I Perez, James M Wright, Jenny MH Chen. 2010. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. .
CrossRef34
Serap Erdine. (2010) Compliance With the Treatment of Hypertension: The Potential of Combination Therapy. The Journal of Clinical Hypertension 12:1, 40-46
CrossRef35
Srikanth Katragadda, Rohit R Arora. (2010) Role of Angiotensin-Converting Enzyme Inhibitors in Vascular Modulation: Beyond the Hypertensive Effects. American Journal of Therapeutics 17:1, e11-e23
CrossRef36
Petra C. van Rijn-Bikker, Gideon Mairuhu, Gert A. van Montfrans, Eric J.G. Sijbrands, Aeilko H. Zwinderman, Henk-Jan Guchelaar, Richard P. Koopmans. (2009) Genetic Factors Are Relevant and Independent Determinants of Antihypertensive Drug Effects in a Multiracial Population. American Journal of Hypertension 22:12, 1295-1302
CrossRef37
Ernst, Michael E., Moser, Marvin, . (2009) Use of Diuretics in Patients with Hypertension. New England Journal of Medicine 361:22, 2153-2164
Full Text38
Jenny MH Chen, Balraj S Heran, James M Wright, Jenny MH Chen. 2009. Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. .
CrossRef39
Vijaya M Musini, Aaron M Tejani, Ken Bassett, James M Wright, Vijaya M Musini. 2009. Pharmacotherapy for hypertension in the elderly. .
CrossRef40
Daniel Kurnik, Andrew J Cunningham, Gbenga G Sofowora, Utkarsh Kohli, Chun Li, Eitan A Friedman, Mordechai Muszkat, Usha B Menon, Alastair JJ Wood, C Michael Stein. (2009) GRK5 Gln41Leu polymorphism is not associated with sensitivity to β 1 -adrenergic blockade in humans. Pharmacogenomics 10:10, 1581-1587
CrossRef41
Barry J. Materson, Eileen M. Bernal. (2009) Inherent inaccuracies and potential utility of race/ethnicity labeling in the treatment of hypertension. Journal of the American Society of Hypertension 3:5, 291-294
CrossRef42
Steven G Chrysant. (2009) Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. Expert Review of Cardiovascular Therapy 7:8, 887-895
CrossRef43
Steven G. Chrysant, Kathleen J. Chavanu, Jianbo Xu. (2009) Combination Therapy with Olmesartan Medoxomil and Hydrochlorothiazide. American Journal Cardiovascular Drugs 9:4, 241-251
CrossRef44
Kelly Makarounas-Kirchmann, Sophie Glover-Koudounas, Paolo Ferrari. (2009) Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clinical Therapeutics 31:8, 1652-1663
CrossRef45
James M Wright, Vijaya M Musini, James M Wright. 2009. First-line drugs for hypertension. .
CrossRef46
(2009) Tiotropium-Lessons from recent studies. Respirology 14:5, 623-624
CrossRef47
Claudio Faria, Marie Wenzel, Karen W. Lee, Karen Coderre, Jake Nichols, Daniel A. Belletti. (2009) A narrative review of clinical inertia: focus on hypertension. Journal of the American Society of Hypertension 3:4, 267-276
CrossRef48
Arash Rashidi, Jackson T. Wright. (2009) Drug Treatment of Hypertension in Older Hypertensives. Clinics in Geriatric Medicine 25:2, 235-244
CrossRef49
Saraswathy Manickavasagam, Ramanna Merla, Michael M Koerner, Ken Fujise, Sanjay Kunapuli, Salvatore Rosanio, Alejandro Barbagelata. (2009) Management of hypertension in chronic heart failure. Expert Review of Cardiovascular Therapy 7:4, 423-433
CrossRef50
Michael Rudnicki, Gert Mayer. (2009) Significance of genetic polymorphisms of the renin–angiotensin–aldosterone system in cardiovascular and renal disease. Pharmacogenomics 10:3, 463-476
CrossRef51
Seul Min Choi, Mi Jeong Seo, Kyung Koo Kang, Jeong Hoon Kim, Byoung Ok Ahn, Moohi Yoo. (2009) Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats. Archives of Pharmacal Research 32:3, 353-358
CrossRef52
Yusuke TANIGAWARA, Kazutaka YOSHIHARA, Kizuku KURAMOTO, Kikuo ARAKAWA. (2009) Comparative Pharmacodynamics of Olmesartan and Azelnidipine in Patients with Hypertension: a Population Pharmacokinetic/Pharmacodynamic Analysis. Drug Metabolism and Pharmacokinetics 24:4, 376-388
CrossRef53
Domenic A. Sica. 2009. Renin–Angiotensin Blockade: Therapeutic Agents. , 189-201.
CrossRef54
Jason G. Umans, Edgardo J. Abalos, Marshall D. Lindheimer. 2009. Antihypertensive Treatment. , 369-387.
CrossRef55
K. F. Hilgers, J. F. E. Mann. (2008) The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?. Nephrology Dialysis Transplantation 23:11, 3389-3391
CrossRef56
George L Bakris. (2008) Response to ‘Diuretics should be used as the second-line agent in combination with RAS inhibitors in proteinuric patients with CKD’1. Kidney International 74:10, 1358-1359
CrossRef57
Chuke E. Nwachuku, Arnaud Bastien, Jeffrey A. Cutler, Glenda M. Grob, Karen L. Margolis, Edward J. Roccella, Sara Pressel, Barry R. Davis, Michael Caso, Sheldon Sheps, Michael Weber. (2008) Management of High Blood Pressure in Clinical Practice: Perceptible Qualitative Differences in Approaches Utilized by Clinicians. The Journal of Clinical Hypertension 10:11, 822-829
CrossRef58
Daniel Kurnik, Chun Li, Gbenga G. Sofowora, Eitan A. Friedman, Mordechai Muszkat, Hong-Guang Xie, Paul A. Harris, Scott M. Williams, Usha B. Nair, Alastair J.J. Wood, C. Michael Stein. (2008) Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenetics and Genomics 18:10, 895-902
CrossRef59
Keith C Norris, Naureen Tareen, David Martins, Nosratola D Vaziri. (2008) Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans. Nature Clinical Practice Nephrology 4:10, 538-549
CrossRef60
William G. Henderson, Philip W. Lavori, Peter Peduzzi, Joseph F. Collins, Mike R. Sather, John R. Feussner. 2008. Cooperative Studies Program, US Department of Veterans Affairs. .
CrossRef61
N. R. Poulter. (2008) Selecting a fixed combination to improve morbidity/mortality: the weight of evidence with ASCOT. European Heart Journal Supplements 10:Suppl G, G21-G28
CrossRef62
Steven G. Chrysant. (2008) Proactive Compared With Passive Adverse Event Recognition: Calcium Channel Blocker-Associated Edema. The Journal of Clinical Hypertension 10:9, 716-722
CrossRef63
Cynthia A Weber, Megan R Leloux, Barry L Carter, Karen B Farris, Yinghui Xu. (2008) Reduction in Adverse Symptoms as Blood Pressure Becomes Controlled. Pharmacotherapy 28:9, 1104-1114
CrossRef64
José R. González-Juanatey, Pilar Mazón Ramos. (2008) Prevención primaria farmacológica en hipertensión arterial y dislipemias. Revista Española de Cardiología 61:8, 861-879
CrossRef65
Jack F. Hollis, Christina M. Gullion, Victor J. Stevens, Phillip J. Brantley, Lawrence J. Appel, Jamy D. Ard, Catherine M. Champagne, Arlene Dalcin, Thomas P. Erlinger, Kristine Funk, Daniel Laferriere, Pao-Hwa Lin, Catherine M. Loria, Carmen Samuel-Hodge, William M. Vollmer, Laura P. Svetkey. (2008) Weight Loss During the Intensive Intervention Phase of the Weight-Loss Maintenance Trial. American Journal of Preventive Medicine 35:2, 118-126
CrossRef66
Melvin R. Hayden, James R. Sowers. (2008) Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. Journal of the American Society of Hypertension 2:4, 239-266
CrossRef67
Setareh A. Williams, Eric L. Michelson, Valerie A. Cain, Min Yang, Shawna D. Nesbitt, Brent M. Egan, Stevo Julius. (2008) An Evaluation of the Effects of an Angiotensin Receptor Blocker on Health-Related Quality of Life in Patients With High-Normal Blood Pressure (Prehypertension) in the Trial of Preventing Hypertension (TROPHY). The Journal of Clinical Hypertension 10:6, 436-442
CrossRef68
A. Pareek, N. Karnik, S. B. Salagre, S. D. Zawar, V. K. Joglekar, N. Chandurkar, G. S. Naik. (2008) Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study. Current Medical Research and Opinion 24:6, 1771-1779
CrossRef69
Dilek Iusuf, Robert H. Henning, Wiek H. van Gilst, Anton J.M. Roks. (2008) Angiotensin-(1–7): Pharmacological properties and pharmacotherapeutic perspectives. European Journal of Pharmacology 585:2-3, 303-312
CrossRef70
Huai-Sheng Chen, Wen JunMin, Jianping Liu, Wu ShengNan, Huai-Sheng Chen. 2008. Catheter ablation for paroxysmal and persistent atrial fibrillation. .
CrossRef71
Jenny MH Chen, Balraj S Heran, Marco I Perez, James M Wright, Jenny MH Chen. 2008. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. .
CrossRef72
He-Hui Xie, Xiao-Fei Zhang, Yuan-Yuan Chen, Fu-Ming Shen, Ding-Feng Su. (2008) Synergism of Hydrochlorothiazide and Nifedipine on Blood Pressure Variability Reduction and Organ Protection in Spontaneously Hypertensive Rats. Hypertension Research 31:4, 685-691
CrossRef73
Diane BMA van Wieren-de Wijer, Olaf H Klungel, Anke-Hilse Maitland-van der Zee. (2008) Are there interactions between the Gly460Trp α-adducin gene variant and the use of diuretics?. Personalized Medicine 5:2, 117-121
CrossRef74
Steven G Chrysant. (2008) Aliskiren–hydrochlorothiazide combination for the treatment of hypertension. Expert Review of Cardiovascular Therapy 6:3, 305-314
CrossRef75
Junichi Minami, Toshihiko Ishimitsu, Hiroaki Matsuoka. (2008) Is There Overlap in Blood-pressure Response to the Blockers of the Renin–Angiotensin System Between Lower and Higher Renin Subjects?. American Journal of Hypertension 21:2, 130-131
CrossRef76
Hengxi Chen, Qi Zhuo, Wei Yuan, Juan Wang, Taixiang Wu, Taixiang Wu. 2008. Vitamin A for preventing acute lower respiratory tract infections in children up to seven years of age. .
CrossRef77
Douglas G. Shemin, Lance D. Dworkin. 2008. Calcium Channel Blockers. , 610-619.
CrossRef78
Steven G Chrysant. (2008) Using Fixed-Dose Combination Therapies to Achieve Blood Pressure Goals. Clinical Drug Investigation 28:11, 713-734
CrossRef79
Andrew Hall, Hamish Dobbie, Giovambattista Capasso, Robert Unwin. 2008. Diuretics and β-Blockers. , 591-600.
CrossRef80
Vincent J Canzanello, Evelyn Baranco-Pryor, Frederic Rahbari-Oskoui, Gary L Schwartz, Eric Boerwinkle, Stephen T Turner, Arlene B Chapman. (2008) Predictors of Blood Pressure Response to the Angiotensin Receptor Blocker Candesartan in Essential Hypertension. American Journal of Hypertension 21:1, 61-66
CrossRef81
G T McInnes. (2007) Antihypertensive drugs in combination: additive or greater than additive?. Journal of Human Hypertension 21:12, 914-916
CrossRef82
Keith Norris, Joel M. Neutel. (2007) Emerging Insights in the First-Step Use of Antihypertensive Combination Therapy. The Journal of Clinical Hypertension 9:s12, 5-14
CrossRef83
Gang LING, Ai-jun LIU, Fu-ming SHEN, Guo-jun CAI, Jian-guo LIU, Ding-feng SU. (2007) Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. Acta Pharmacologica Sinica 28:11, 1755-1760
CrossRef84
Anthony J. Bella, Ling X. DeYoung, Mussa al-Numi, Gerald B. Brock. (2007) Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications. European Urology 52:4, 990-1005
CrossRef85
Carla B.C. Gonçalves, Leila B. Moreira, Miguel Gus, Flávio D. Fuchs. (2007) Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting. European Journal of Clinical Pharmacology 63:10, 973-978
CrossRef86
M Muszkat. (2007) Interethnic Differences in Drug Response: The Contribution of Genetic Variability in β Adrenergic Receptor and Cytochrome P4502C9. Clinical Pharmacology & Therapeutics 82:2, 215-218
CrossRef87
Sripal Bangalore, Gayathri Kamalakkannan, Sanobar Parkar, Franz H. Messerli. (2007) Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. The American Journal of Medicine 120:8, 713-719
CrossRef88
Jaekyu Shin, Julie A Johnson. (2007) Pharmacogenetics of β-Blockers. Pharmacotherapy 27:6, 874-887
CrossRef89
Robert M. Carey. (2007) Phosphodiesterase type V: A novel therapeutic target for hypertension. Current Hypertension Reports 9:2, 119-120
CrossRef90
Mahmoud M El-Mas, Abdel A Abdel-Rahman. (2007) Intermittent Clonidine Regimen Abolishes Tolerance to Its Antihypertensive Effect: A Spectral Study. Journal of Cardiovascular Pharmacology 49:3, 174-181
CrossRef91
Roberto Fogari, GianDomenico Malamani, Annalisa Zoppi, Amedeo Mugellini, Andrea Rinaldi, Elena Fogari, Tiziano Perrone. (2007) Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: A three-way crossover study. Clinical Therapeutics 29:3, 413-418
CrossRef92
K M Giacomini, C M Brett, R B Altman, N L Benowitz, M E Dolan, D A Flockhart, J A Johnson, D F Hayes, T Klein, R M Krauss, D L Kroetz, H L McLeod, A T Nguyen, M J Ratain, M V Relling, V Reus, D M Roden, C A Schaefer, A R Shuldiner, T Skaar, K Tantisira, R F Tyndale, L Wang, R M Weinshilboum, S T Weiss, I Zineh. (2007) The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response. Clinical Pharmacology & Therapeutics 81:3, 328-345
CrossRef93
Charles Shey U. Wiysonge, Hazel A Bradley, Bongani M Mayosi, Roy T Maroney, Anthony Mbewu, Lionel Opie, Jimmy Volmink, Charles Shey U. Wiysonge. 2007. Beta-blockers for hypertension. .
CrossRef94
Benjamin J Epstein, Katherine Vogel, Biff F Palmer. (2007) Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension. Drugs 67:9, 1309-1327
CrossRef95
W.J. Elliott. (2007) Improving Blood Pressure Control through Provider Education, Provider Alerts, and Patient Education: A Cluster Randomized Trial. Yearbook of Cardiology 2007, 90-92
CrossRef96
James L. Pool, Robert Glazer, Myron Weinberger, Roxanne Alvarado, Jie Huang, Alan Graff. (2007) Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clinical Therapeutics 29:1, 61-73
CrossRef97
William C. Cushman, Jan Basile. (2006) Achieving Blood Pressure Goals: Why Aren't We?. The Journal of Clinical Hypertension 8:12, 865-871
CrossRef98
Ping HAN, Zheng-xu CHU, Fu-ming SHEN, He-hui XIE, Ding-feng SU. (2006) Synergism of hydrochlorothiazide and nitrendipine on reduction of blood pressure and blood pressure variability in spontaneously hypertensive rats. Acta Pharmacologica Sinica 27:12, 1575-1579
CrossRef99
Jean-Philippe Baguet, Gilles Barone-Rochette, Jean-Michel Mallion. (2006) European Society of Hypertension Scientific Newsletter: hypertension and coronary heart disease. Journal of Hypertension 24:11, 2323-2325
CrossRef100
MARTIN GALLAGHER, VLADO PERKOVIC, JOHN CHALMERS. (2006) Diuretics: A modern day treatment option? (Review Article). Nephrology 11:5, 419-427
CrossRef101
Robert D. Toto. (2006) Lessons from the African-American study of kidney disease and hypertension: An update. Current Hypertension Reports 8:5, 409-412
CrossRef102
Issam Zineh, Julie A Johnson. (2006) Pharmacogenetics of chronic cardiovascular drugs: applications and implications. Expert Opinion on Pharmacotherapy 7:11, 1417-1427
CrossRef103
Rainer Düsing. (2006) Overcoming barriers to effective blood pressure control in patients with hypertension. Current Medical Research and Opinion 22:8, 1545-1553
CrossRef104
Kevin M. O'Shaughnessy, Fiona E. Karet. (2006) Salt Handling and Hypertension. Annual Review of Nutrition 26:1, 343-365
CrossRef105
Debbie L. Cohen, Raymond R. Townsend. (2006) Following Up Angiotensin-Converting Enzyme Inhibitor Monotherapy. The Journal of Clinical Hypertension 8:8, 600-601
CrossRef106
Marcel Ruzicka, Frans H. H. Leenen. (2006) Moving beyond guidelines: Are report cards the answer to high rates of uncontrolled hypertension?. Current Hypertension Reports 8:4, 324-329
CrossRef107
Stephanie Maciejewski, Syed M Mohiuddin, Kathleen A Packard, Aryan N Mooss, Antonio P Reyes, Arash Aryana, Daniel E Hilleman. (2006) Randomized, Double-Blind, Crossover Comparison of Amlodipine and Valsartan in African-Americans with Hypertension Using 24-Hour Ambulatory Blood Pressure Monitoring. Pharmacotherapy 26:7, 889-895
CrossRef108
C. S. Stump, M. T. Hamilton, J. R. Sowers. (2006) Effect of Antihypertensive Agents on the Development of Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 81:6, 796-806
CrossRef109
Judy W.M. Cheng. (2006) A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clinical Therapeutics 28:5, 666-678
CrossRef110
A. Ferro, R. Gilbert, H. Krum. (2006) Importance of renin in blood pressure regulation and therapeutic potential of renin inhibition. International Journal of Clinical Practice 60:5, 577-581
CrossRef111
D de Zeeuw, D Ramjit, Z Zhang, A B Ribeiro, K Kurokawa, J P Lash, J Chan, G Remuzzi, B M Brenner, S Shahinfar. (2006) Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney International 69:9, 1675-1682
CrossRef112
Troy Bremer, Albert Man, Kalev Kask, Cornelius Diamond. (2006) CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics 7:3, 271-279
CrossRef113
Alejandro de la Sierra. (2006) Valor de la presión de pulso como marcador de riesgo cardiovascular. Medicina Clínica 126:10, 24-28
CrossRef114
Fernando de ??lvaro, Miguel Angel Hern??ndez-Presa. (2006) Effect of Doxazosin Gastrointestinal Therapeutic System on Patients with Uncontrolled Hypertension: The ASOCIA Study. Journal of Cardiovascular Pharmacology 47:2, 271-276
CrossRef115
M Mohsen Ibrahim. (2006) RAS inhibition in hypertension. Journal of Human Hypertension 20:2, 101-108
CrossRef116
Michio FUKUDA, Genjiro KIMURA. (2006) Pathophysiology of Antihypertensive Therapy with Diuretics. Hypertension Research 29:9, 645-653
CrossRef117
Keith C. Ferdinand, Elijah Sounders. (2006) Hypertension-Related Morbidity and Mortality in African Americans?Why We Need to Do Better. The Journal of Clinical Hypertension 8:s1, 21-30
CrossRef118
W.J. Elliott. (2006) Ethnic Differences in Blood Pressure Control Among Men at Veterans Affairs Clinics and Other Health Care Sites. Yearbook of Cardiology 2006, 9-11
CrossRef119
Elizabeth O. Ofili. (2006) Dispelling the Myth of "Aggressive" Antihypertensive Therapy. The Journal of Clinical Hypertension 8:s1, 4-11
CrossRef120
Japanese Society of Hypertension. (2006) Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertension Research 29:Suppl, S1-S106
CrossRef121
Barbara Gidaro, Chiara Lonati, Maria Garagiola, Enrica Periti, Alberto Morganti. (2006) Hypertension and Erectile Dysfunction. High Blood Pressure & Cardiovascular Prevention 13:1, 7-11
CrossRef122
Li-Hua Lu, He-Hui Xie, Guo-Jun Cai, Fu-Ming Shen, Ding-Feng Su. (2005) Diminished Responses to Nifedipine Imply Severe End-Organ Damage in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology 46:6, 836-841
CrossRef123
Stephen G. Schwartz, Brian J. Puckett, Robert C. Allen, Ivan G. Castillo, Christopher T. Leffler. (2005) β1-Adrenergic Receptor Polymorphisms and Clinical Efficacy of Betaxolol Hydrochloride in Normal Volunteers. Ophthalmology 112:12, 2131-2136
CrossRef124
U. S. R. Helfrich, M. Schley, G. A. Petroianu, J. Schmeck, C. Konrad. (2005) Clonidine increases membrane-associated phospholipase A2. European Journal of Anaesthesiology 22:12, 942-946
CrossRef125
Domenic A. Sica. (2005) Alpha 1 -Adrenergic Blockers: Current Usage Considerations. The Journal of Clinical Hypertension 7:12, 757-762
CrossRef126
Shakaib U Rehman, Jan Basile. (2005) Calcium channel blockers in the elderly: current status in the treatment of hypertension. Aging Health 1:3, 419-434
CrossRef127
Shanchun Zhang, Guangyun Mao, Yan Zhang, Genfu Tang, Yufeng Wen, Xiumei Hong, Shanqun Jiang, Yunxian Yu, Xiping Xu. (2005) Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in Rural Chinese patients with essential hypertension. Clinical Therapeutics 27:11, 1774-1784
CrossRef128
Fu-ming SHEN, He-hui XIE, Gang LING, Li-ping XU, Ding-feng SU. (2005) Synergistic effects of atenolol and amlodipine for lowering and stabilizing blood pressure in 2K1C renovascular hypertensive rats1. Acta Pharmacologica Sinica 26:11, 1303-1308
CrossRef129
Andrew B Covit. (2005) Medical treatment of renal artery stenosis: is it effective and appropriate?. Journal of Hypertension 23:Suppl 3, S15-S22
CrossRef130
George L. Bakris, David H.G. Smith, Thomas D. Giles, William B. White, Giora Davidai, Michael A. Weber. (2005) Comparative Antihypertensive Efficacy of Angiotensin Receptor Blocker-Based Treatment in African-American and White Patients. The Journal of Clinical Hypertension 7:10, 587-597
CrossRef131
David Webb, W Stephen Waring. 2005. Antihypertensive Drugs. , 165-200.
CrossRef132
Susanne B. Nicholas, Naureen Tareen, Ashraf Zadshir, David Martins, Deyu Pan, Keith C. Norris. (2005) Management of early chronic kidney disease in indigenous populations and ethnic minorities. Kidney International 68:s97, S78-S81
CrossRef133
Cora Muñoz, Cheryl Hilgenberg. (2005) Ethnopharmacology. AJN, American Journal of Nursing 105:8, 40-48
CrossRef134
William G. Henderson, Philip W. Lavori, Peter Peduzzi, Joseph F. Collins, Mike R. Sather, John R. Feussner. 2005. Cooperative Studies Program, US Department of Veterans Affairs. .
CrossRef135
Addison A. Taylor, James L. Pool. (2005) Clinical Pharmacology of Antihypertensive Therapy. Seminars in Nephrology 25:4, 215-226
CrossRef136
Philip B Mellen, David M Herrington. (2005) Pharmacogenomics of blood pressure response to antihypertensive treatment. Journal of Hypertension 23:7, 1311-1325
CrossRef137
John Kabal, Bruce K. Lagerman. (2005) Computer-Aided Clinical Decision System: Differential Diagnosis and Treatment of Essential Hypertension by a Novel Noninvasive Hemodynamic Analyzer. Cardiovascular Engineering 5:2, 83-96
CrossRef138
Thomas W. Wallace, Mark H. Drazner. (2005) The impact of race on response to RAAS inhibition. Current Heart Failure Reports 2:2, 72-77
CrossRef139
Steven A Claas, Stephen P Glasser. (2005) Long-acting diltiazem HCL for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris. Expert Opinion on Pharmacotherapy 6:5, 765-776
CrossRef140
Anke-Hilse Maitland-van der Zee, Stephen T. Turner, Gary L. Schwartz, Arlene B. Chapman, Olaf H. Klungel, Eric Boerwinkle. (2005) A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenetics and Genomics 15:5, 287-293
CrossRef141
William B. White, Timothy Moon. (2005) Treatment of Benign Prostatic Hyperplasia in Hypertensive Men. The Journal of Clinical Hypertension 7:4, 212-217
CrossRef142
A. Galioto, P. Angeli, S. Guarda, P. Burra, G. Zanus, S. Fasolato, S. Fagiuoli, A. Sticca, A. Semplicini, M. Sartori, A. Carraro, P. Boccagni, U. Cillo, A. Gatta. (2005) Comparison Between Nifedipine and Carvedilol in the Treatment of de novo Arterial Hypertension After Liver Transplantation: Preliminary Results of a Controlled Clinical Trial. Transplantation Proceedings 37:2, 1245-1247
CrossRef143
Hardeep Singh, Michael L. Johnson. (2005) Prescribing Patterns of Diuretics in Multi-Drug Antihypertensive Regimens. The Journal of Clinical Hypertension 7:2, 81-89
CrossRef144
Robert A. Phillips. (2005) Diuretics Should Continue to Be One of the Preferred Initial Therapies in the Management of Hypertension. The Journal of Clinical Hypertension 7:2, 111-116
CrossRef145
Lizzy L.M. Brewster, Jos Kleijnen, Gert G van Montfrans, Lizzy L.M. Brewster. 2005. Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks. .
CrossRef146
He-Hui Xie, Chao-Yu Miao, Yuan-Ying Jiang, Ding-Feng Su. (2005) Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats. Journal of Hypertension 23:1, 193-201
CrossRef147
(2005) Should We Routinely Measure Renin Levels to Diagnose and Treat Patients With Hypertension?. The Journal of Clinical Hypertension 7:1, 33-35
CrossRef148
Jan A. STAESSEN, Yan LI, Lutgarde THIJS, Ji-Guang WANG. (2005) Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials. Hypertension Research 28:5, 385-407
CrossRef149
Steffen Böhler, David Pittrow, Peter Bramlage, Wilhelm Kirch. (2005) Drug interactions with angiotensin receptor blockers. Expert Opinion on Drug Safety 4:1, 7-18
CrossRef150
Rainer D??sing. (2005) Sexual Dysfunction in Male Patients with Hypertension. Drugs 65:6, 773-786
CrossRef151
Jan Basile. (2004) The Role of Existing and Newer Calcium Channel Blockers in the Treatment of Hypertension. The Journal of Clinical Hypertension 6:11, 621-629
CrossRef152
Anjanette S. Tan, Saravanan Kuppuswamy, Adam T. Whaley-Connell, L Romayne Kurukulasuriya, James R. Sowers. (2004) Recommendations for Special Populations. The Endocrinologist 14:6, 368-381
CrossRef153
Tiina Podymow, Phyllis August, Jason G. Umans. (2004) Antihypertensive therapy in pregnancy. Seminars in Nephrology 24:6, 616-625
CrossRef154
L. Welsh, A. Ferro. (2004) Drug treatment of essential hypertension: the case for initial combination therapy. International Journal of Clinical Practice 58:10, 956-963
CrossRef155
Marvin Moser. (2004) Update on the Management of Hypertension: Recent Clinical Trials and the JNC 7. The Journal of Clinical Hypertension 6:s10, 4-13
CrossRef156
Thomas G. Pickering. (2004) Treatment of Hypertension in the Elderly. The Journal of Clinical Hypertension 6:s10, 18-23
CrossRef157
David E Lanfear, Sharon Marsh, Sharon Cresci, John A Spertus, Howard L McLeod. (2004) Frequency of compound genotypes associated with β-blocker efficacy in congestive heart failure. Pharmacogenomics 5:5, 553-558
CrossRef158
Lyne Lalonde, Annette M. O’Connor, Elizabeth Drake, Pierrette Duguay, Ilka Lowensteyn, Steven A. Grover. (2004) Development and Preliminary Testing of a Patient Decision Aid to Assist Pharmaceutical Care in the Prevention of Cardiovascular Disease. Pharmacotherapy 24:7, 909-922
CrossRef159
Vasilios Papademetriou, Puneet Narayan, Peter Kokkinos. (2004) Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in African-American Patients With Hypertension. The Journal of Clinical Hypertension 6:6, 310-314
CrossRef160
Ettore Malacco, Simona Piazza, Luciana Scandiani, Annalisa Zoppi. (2004) Effects of valsartan/ hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients. Advances in Therapy 21:3, 149-161
CrossRef161
Joel M. Neutel, David H.G. Smith, Micheal A. Weber, Antonia C. Wang, Harvey N. Masonson. (2004) Use of an Olmesartan Medoxomil-Based Treatment Algorithm for Hypertension Control. The Journal of Clinical Hypertension 6:4, 168-399
CrossRef162
Kenneth A. Jamerson. (2004) The Disproportionate Impact of Hypertensive Cardiovascular Disease in African Americans: Getting to the Heart of the Issue. The Journal of Clinical Hypertension 6:s4, 4-10
CrossRef163
Massimo Volpe. (2004) Hypertension therapy: Mixing, matching, and meeting targets. Advances in Therapy 21:2, 107-122
CrossRef164
Li-Ping Xu, Fu-Ming Shen, He Shu, Chao-Yu Miao, Yuan-Ying Jiang, Ding-Feng Su. (2004) Synergism of atenolol and amlodipine on lowering and stabilizing blood pressure in spontaneously hypertensive rats. Fundamental and Clinical Pharmacology 18:1, 33-38
CrossRef165
Sheng Kang, Yang Feng Wu, Ning An, MingBao Ren. (2004) A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clinical Therapeutics 26:2, 257-270
CrossRef166
Gary L Schwartz, Stephen T Turner. (2004) Pharmacogenetics of Antihypertensive Drug Responses. American Journal of PharmacoGenomics 4:3, 151-160
CrossRef167
Marvin Moser, John Setaro. (2004) Continued importance of diuretics and β-adrenergic blockers in the management of hypertension. Medical Clinics of North America 88:1, 167-187
CrossRef168
Hedi Schelleman, Bruno H Ch Stricker, Anthonius de Boer, Abraham A Kroon, Monique W M Verschuren, Cornelia M van Duijn, Bruce M Psaty, Olaf H Klungel. (2004) Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy. Drugs 64:16, 1801-1816
CrossRef169
Richard P Koopmans, Paul A Insel, Martin C Michel. (2003) Pharmacogenetics of hypertension treatment. Pharmacogenetics 13:12, 705-713
CrossRef170
Peter A. Ubel, Christopher Jepson, David A. Asch. (2003) Misperceptions About beta-Blockers and Diuretics. A National Survey of Primary Care Physicians. Journal of General Internal Medicine 18:12, 977-983
CrossRef171
Michael A Weber. (2003) Yet more hypertension guidelines. Journal of Hypertension 21:11, 1977-1981
CrossRef172
William H. Frishman. (2003) The evolving role of diltiazem hydrochloride in cardiovascular management. Clinical Cardiology 26:S4, 5-9
CrossRef173
Renke Maas, Rainer H Böger. (2003) Antihypertensive therapy: special focus on drug interactions. Expert Opinion on Drug Safety 2:6, 549-579
CrossRef174
Steven G Chrysant. (2003) Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan®/HCT). Expert Review of Cardiovascular Therapy 1:3, 335-343
CrossRef175
John B. Kostis. (2003) Treatment of Hypertension in Older Patients: An Updated Look at the Role of Calcium Antagonists. The American Journal of Geriatric Cardiology 12:5, 319-327
CrossRef176
Gordon T. Mclnnes. (2003) The Differences Between ACE Inhibitor-Treated and Calcium Channel Blocker-Treated Hypertensive Patients. The Journal of Clinical Hypertension 5:5, 337-344
CrossRef177
Robert L. Scott. (2003) Is Heart Failure in African Americans a Distinct Entity?. Congestive Heart Failure 9:4, 193-196
CrossRef178
Donald J. Naismith, Alessandro Braschi. (2003) The effect of low-dose potassium supplementation on blood pressure in apparently healthy volunteers. British Journal of Nutrition 90:01, 53
CrossRef179
Michael A. Weber. (2003) Creating a Combination Antihypertensive Regimen: What Does the Research Show?. The Journal of Clinical Hypertension 5:4, 12-20
CrossRef180
Michael A. Weber. (2003) The JNC 7 Report: Challenges and Dilemmas in Writing Guidelines. The Journal of Clinical Hypertension 5:4, 282-286
CrossRef181
Jan A Staessen, Ji-Guang Wang, Lutgarde Thijs. (2003) Cardiovascular prevention and blood pressure reduction. Journal of Hypertension 21:6, 1055-1076
CrossRef182
Bernard Waeber. (2003) Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Review of Cardiovascular Therapy 1:1, 43-50
CrossRef183
Barry J. Materson, David W. Williams, Domenic J. Reda, William C. Cushman, . (2003) Response to Six Classes of Antihypertensive Medications by Body Mass Index in a Randomized Controlled Trial. The Journal of Clinical Hypertension 5:3, 197-201
CrossRef184
Paul G. Shekelle, Michael W. Rich, Sally C. Morton, Col.Sid W. Atkinson, Wenli Tu, Margaret Maglione, Shannon Rhodes, Michael Barrett, Gregg C. Fonarow, Barry Greenberg, Paul A. Heidenreich, Tom Knabel, Marvin A. Konstam, Anthony Steimle, Lynne Warner Stevenson. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. Journal of the American College of Cardiology 41:9, 1529-1538
CrossRef185
John M. Flack, Samar A. Nasser. (2003) Clinical Trials Report. Current Hypertension Reports 5:3, 189-191
CrossRef186
Keith Norris, Charles Vaughn. (2003) The role of renin–angiotensin– aldosterone system inhibition in chronic kidney disease. Expert Review of Cardiovascular Therapy 1:1, 51-63
CrossRef187
Deborah A. Price, Naomi D. L. Fisher. (2003) The renin-angiotensin system in blacks: Active, passive, or what?. Current Hypertension Reports 5:3, 225-230
CrossRef188
Benjamin M. Schaefer, Vincent Caracciolo, William H. Frishman, Pamela Charney. (2003) Gender, Ethnicity, and Genes in Cardiovascular Disease.. Heart Disease 5:3, 202-214
CrossRef189
John M Flack, Suzanne Oparil, J.Howard Pratt, Barbara Roniker, Susan Garthwaite, Jay H Kleiman, Yonghong Yang, Scott L Krause, Diane Workman, Elijah Saunders. (2003) Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. Journal of the American College of Cardiology 41:7, 1148-1155
CrossRef190
Steven E Lipshultz, Stacy D Fisher, Wyman W Lai, Tracie L Miller. (2003) Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 17, S96-S122
CrossRef191
Frohlich, Edward D., . (2003) Treating Hypertension — What Are We to Believe?. New England Journal of Medicine 348:7, 639-641
Full Text192
August, Phyllis, . (2003) Initial Treatment of Hypertension. New England Journal of Medicine 348:7, 610-617
Full Text193
C. Venkata, S. Ram. (2003) Getting to goal in complex patients. Clinical Cardiology 26:S2, 3-6
CrossRef194
N. R. Bindraban, G. A. Montfrans. (2003) Hypertensie bij allochtonen in Nederland. Bijblijven 19:2, 50-55
CrossRef195
Bradley R Williams, Jiwon Kim. (2003) Cardiovascular Drug Therapy in the Elderly: Theoretical and Practical Considerations. Drugs & Aging 20:6, 445-463
CrossRef196
Thomas Unger, Elena Kaschina. (2003) Drug Interactions with Angiotensin Receptor Blockers: A Comparison with Other Antihypertensives. Drug Safety 26:10, 707-720
CrossRef197
Elijah Saunders, James R. Gavin. (2003) Blockade of the Renin-Angiotensin System in African Americans With Hypertension and Cardiovascular Disease. The Journal of Clinical Hypertension 5:1, 12-17
CrossRef198
Michael A. Weber. (2003) The ALLHAT Report: A Case of Information and Misinformation. The Journal of Clinical Hypertension 5:1, 9-13
CrossRef199
W O Erhun, E O Agbani, E E Bolaji. (2003) Managing Hypertension with Combination Diuretics and Methyldopa in Nigerian Blacks at???the???Primary Care Level. Clinical Drug Investigation 23:9, 583-590
CrossRef200
Mark R Nelson, Chris M Reid, Henry Krum, John J McNeil. (2003) Factors Influencing Family Physician Adherence to Hypertension Treatment Guideline Recommendations on the Initiation of Pharmacotherapy. American Journal of Cardiovascular Drugs 3:6, 437-441
CrossRef201
Peter E. Cadman, Daniel T. OʼConnor. (2003) Pharmacogenomics of hypertension. Current Opinion in Nephrology and Hypertension 12:1, 61-70
CrossRef202
Reza Tabrizchi. (2003) Dual ACE and Neutral Endopeptidase Inhibitors. Drugs 63:20, 2185-2202
CrossRef203
J STANLEY, R SAMSON. (2002) Treatment of hypertension from volume to vasoconstriction: The ACE up your sleeve. Seminars in Vascular Surgery 15:4, 225-236
CrossRef204
Ehud Grossman, Franz H. Messerli. (2002) Why β-blockers are not cardioprotective in elderly patients with hypertension. Current Cardiology Reports 4:6, 468-473
CrossRef205
Donald RJ Singer, Teck K Khong. (2002) Adverse drug reactions: current issues and strategies for prevention and management. Expert Opinion on Pharmacotherapy 3:9, 1289-1300
CrossRef206
Jay N. Cohn. (2002) Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? pro position. Current Hypertension Reports 4:4, 307-310
CrossRef207
Bernard Waeber. (2002) Fixed low-dose combination therapy for hypertension. Current Hypertension Reports 4:4, 298-306
CrossRef208
L. Michael Prisant. (2002) Should β Blockers Be Used in the Treatment of Hypertension in the Elderly?. The Journal of Clinical Hypertension 4:4, 286-294
CrossRef209
Cheryl L Laffer, Fernando Elijovich. (2002) Essential Hypertension of Caribbean Hispanics: Sodium, Renin, and Response to Therapy. The Journal of Clinical Hypertension 4:4, 266-273
CrossRef210
Domenic A. Sica. (2002) Doxazosin and Congestive Heart Failure. Congestive Heart Failure 8:3, 178-184
CrossRef211
Alison J. Deary, Anne L. Schumann, Helen Murfet, Stephen F. Haydock, Roger S.-Y. Foo, Morris J. Brown. (2002) Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. Journal of Hypertension 20:4, 771-777
CrossRef212
Peter R Jackson. (2002) Economics of drug treatment. The Lancet 359:9309, 892-893
CrossRef213
Arlene B. Chapman, Gary L. Schwartz, Eric Boerwinkle, Stephen T. Turner. (2002) Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney International 61:3, 1047-1055
CrossRef214
Steven G. Terra, Julie A. Johnson. (2002) Pharmacogenetics, Pharmacogenomics, and Cardiovascular Therapeutics. American Journal of Cardiovascular Drugs 2:5, 287-296
CrossRef215
Domenic A. Sica. (2002) Rationale for Fixed-Dose Combinations in the Treatment of Hypertension. Drugs 62:3, 443-462
CrossRef216
James A. Blumenthal, Andrew Sherwood, Elizabeth C. D. Gullette, Anastasia Georgiades, Damon Tweedy. (2002) Biobehavioral approaches to the treatment of essential hypertension.. Journal of Consulting and Clinical Psychology 70:3, 569-589
CrossRef217
Carlos Campo, Julián Segura, Luis M. Ruilope. (2002) Factors Influencing the Systolic Blood Pressure Response to Drug Therapy. The Journal of Clinical Hypertension 4:1, 35-40
CrossRef218
S.K. Hildemann, H. Fischer, D. Pittrow, V. Bohlscheid. (2002) Metoprolol Succinate SR plus Hydrochlorothiazide (Beloc-Zok?? Comp) in Patients with Essential Hypertension in General Practice. Clinical Drug Investigation 22:11, 719-729
CrossRef219
&NA;. (2002) Combination therapy: complementary mechanisms have potential advantages in the initial management of uncomplicated hypertension. Drugs & Therapy Perspectives 18:1, 6-8
CrossRef220
Roberto Antonicelli, Stefano Omboni, Di Ci?? Giovanni, Roberto Ansuini, Alfredo Mori, Rosaria Gesuita, Gianfranco Parati, Enrico Paciaroni. (2002) Smooth Blood Pressure Control Obtained with Extended-Release Felodipine in Elderly Patients with Hypertension. Drugs & Aging 19:7, 541-551
CrossRef221
Samuel J. Mann, Linda M. Gerber. (2002) Psychological Characteristics and Responses to Antihypertensive Drug Therapy. The Journal of Clinical Hypertension 4:1, 25-34
CrossRef222
Sharon See. (2001) Angiotensin II receptor blockers for the treatment of hypertension. Expert Opinion on Pharmacotherapy 2:11, 1795-1804
CrossRef223
STEVEN E. LIPSHULTZ, STACY D. FISHER, WYMAN W. LAI, TRACIE L. MILLER. (2001) Cardiovascular Monitoring and Therapy for HIV-Infected Patients. Annals of the New York Academy of Sciences 946:1, 236-273
CrossRef224
Mátyás Keltai, Julie A. Johnson, L. Douglas Ried, Peter R. Kowey, Michael Tueth. (2001) INVEST substudies: Design and patient characteristics. Clinical Cardiology 24:S5, V-9-V-11
CrossRef225
Keith C. Ferdinand. (2001) Advances in Antihypertensive Combination Therapy: Benefits of Low-Dose Thiazide Diuretics in Conjunction With Omapatrilat, a Vasopeptidase Inhibitor. The Journal of Clinical Hypertension 3:5, 307-312
CrossRef226
Donald G. Vidt. (2001) The effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis. Current Hypertension Reports 3:5, 379-380
CrossRef227
Elizabeth Connelly Kudzma. (2001) Cultural Competence: Cardiovascular Medications. Progress in Cardiovascular Nursing 16:4, 152-161
CrossRef228
Stephen T. Turner, Gary L. Schwartz, Arlene B. Chapman, Eric Boerwinkle. (2001) Use of gene markers to guide antihypertensive therapy. Current Hypertension Reports 3:5, 410-415
CrossRef229
Edward D. Freis. (2001) Low-Dose Combination Therapy: Why Include a Diuretic?. The Journal of Clinical Hypertension 3:5, 273-275
CrossRef230
John M. Flack, Elijah Saunders, Alan Gradman, William E. Kraus, F.Martin Lester, J.Howard Pratt, Michael Alderman, Stephen Green, Ramon Vargas, Melanie Espenshade, Paulette Ceesay, Joe Alexander, Allan Goldberg. (2001) Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clinical Therapeutics 23:8, 1193-1208
CrossRef231
Dirk C. Felmeden, Gregory Y. H. Lip. (2001) Resistant hypertension and the birmingham hypertension square. Current Hypertension Reports 3:3, 203-208
CrossRef232
Luis M. Ruilope. (2001) Problems in the control of systolic blood pressure. Current Hypertension Reports 3:3, 173-174
CrossRef233
Janet B. McGill, Paul A. Reilly. (2001) Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clinical Therapeutics 23:6, 833-850
CrossRef234
The Beta-Blocker Evaluation of Survival Trial Investigators. (2001) A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure. New England Journal of Medicine 344:22, 1659-1667
Full Text235
Yancy, Clyde W., Fowler, Michael B., Colucci, Wilson S., Gilbert, Edward M., Bristow, Michael R., Cohn, Jay N., Lukas, Mary Ann, Young, Sarah T., Packer, Milton, . (2001) Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure. New England Journal of Medicine 344:18, 1358-1365
Full Text236
John I.S. Robertson. (2001) A critique of hypertension treatment trials and of their evaluation. Journal of Evaluation in Clinical Practice 7:2, 149-164
CrossRef237
Marvin Moser. (2001) Diuretics Revisited?Again. The Journal of Clinical Hypertension 3:3, 136-138
CrossRef238
C. Campo, J. Segura, M.L. Fernández, L. Guerrero, Helle Christiansen, L.M. Ruilope. (2001) A Prospective Comparison of Four Antihypertensive Agents in Daily Clinical Practice. The Journal of Clinical Hypertension 3:3, 139-144
CrossRef239
Hong-Guang Xie, Victor Dishy, Gbenga Sofowora, Richard B. Kim, Ruth Landau, Richard M. Smiley, Hong-Hao Zhou, Alastair J. J. Wood, Paul Harris, C. Michael Stein. (2001) Arg389Gly ??1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 11:3, 191-197
CrossRef240
Hong-Guang Xie, Richard B Kim, Alastair JJ Wood, C Michael Stein. (2001) M
OLECULAR BASIS OF ETHNIC DIFFERENCES IN DRUG DISPOSITION AND RESPONSE . Annual Review of Pharmacology and Toxicology 41:1, 815-850
CrossRef241
Pitt O. Lim, William F. Young, Thomas M. MacDonald. (2001) A review of the medical treatment of primary aldosteronism. Journal of Hypertension 19:3, 353-361
CrossRef242
C. Michael Stein, Chim C. Lang, Hong-Guang Xie, Alastair J. J. Wood. (2001) Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. Pharmacogenetics 11:2, 95-110
CrossRef243
Jean-Paul Emeriau, Heinrich Knauf, Juan Ocon Pujadas, Carlos Calvo-Gomez, Giuseppe Abate, Gastone Leonetti, Claude Chastang. (2001) A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. Journal of Hypertension 19:2, 343-350
CrossRef244
Sacks, Frank M., Svetkey, Laura P., Vollmer, William M., Appel, Lawrence J., Bray, George A., Harsha, David, Obarzanek, Eva, Conlin, Paul R., Miller, Edgar R., Simons-Morton, Denise G., Karanja, Njeri, Lin, Pao-Hwa, Aickin, Mikel, Most-Windhauser, Marlene M., Moore, Thomas J., Proschan, Michael A., Cutler, Jeffrey A., . (2001) Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. New England Journal of Medicine 344:1, 3-10
Full Text245
Una Martin, Fidelma Dunne, Martin Kendall. (2001) Hypertension in Diabetes Mellitus. Drugs 61:10, 1531-1533
CrossRef246
Marcel Ruzicka, Frans H.H. Leenen. (2001) Monotherapy versus Combination Therapy as First Line Treatment of Uncomplicated Arterial Hypertension. Drugs 61:7, 943-954
CrossRef247
Laura A. Magee. (2001) Treating Hypertension in Women of Child-Bearing Age and during Pregnancy. Drug Safety 24:6, 457-474
CrossRef248
Javier Mar, Fernando Rodríguez-Artalejo. (2001) Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance?. Journal of Hypertension 19:1, 149-155
CrossRef249
Michele A Faulkner, Daniel E Hilleman. (2001) Amlodipine/benazepril: fixed dose combination therapy for hypertension. Expert Opinion on Pharmacotherapy 2:1, 165-178
CrossRef250
Stephen T. Turner, Gary L. Schwartz, Arlene B. Chapman, W. Dallas Hall, Eric Boerwinkle. (2001) Antihypertensive pharmacogenetics: getting the right drug into the right patient. Journal of Hypertension 19:1, 1-11
CrossRef251
Janet B. Mcgill, Paul A. Reilly. (2001) Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clinical Cardiology 24:1, 66-72
CrossRef252
David J. Triggle. 2000. Pharmacodynamics. .
CrossRef253
Karen S Mark, Thomas P Davis. (2000) Stroke: development, prevention and treatment with peptidase inhibitors
. Peptides 21:12, 1965-1973
CrossRef254
Krista A. Payne, Sahra Esmonde-White. (2000) Observational studies of antihypertensive medication use and compliance: Is drug choice a factor in treatment adherence?. Current Hypertension Reports 2:6, 515-524
CrossRef255
Eric L. Knight, Robert J. Glynn, Raisa Levin, David A. Ganz, Jerry Avorn. (2000) Failure of Evidence-based Medicine in the Treatment of Hypertension in Older Patients. Journal of General Internal Medicine 15:10, 702-709
CrossRef256
Jody Piltz, Ronald Gross, Dong H Shin, Julia A Beiser, David A Dorr, Michael A Kass, Mae O Gordon. (2000) Contralateral effect of topical β-adrenergic antagonists in initial one-eyed trials in the Ocular Hypertension Treatment Study. American Journal of Ophthalmology 130:4, 441-453
CrossRef257
Jordan R. Asher, Allen J. Naftilan. (2000) Vasopeptidase inhibition: A new direction in cardiovascular treatment. Current Hypertension Reports 2:4, 384-391
CrossRef258
Lennart Hansson, Thomas Hedner, Per Lund-Johansen, Sverre Erik Kjeldsen, Lars H Lindholm, Jan Otto Syvertsen, Jan Lanke, Ulf de Faire, Björn Dahlöf, Bengt E Karlberg. (2000) Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. The Lancet 356:9227, 359-365
CrossRef259
Charles P. Tifft. (2000) Joint national committee VI: Individualized versus indiscriminate therapy for hypertension. Current Hypertension Reports 2:3, 243-246
CrossRef260
David Siegel. (2000) The influence of national guidelines on antihypertensive prescribing patterns. Current Hypertension Reports 2:3, 247-252
CrossRef261
Jirí Widimský. (2000) The fixed combination of verapamil SR/trandolapril. Expert Opinion on Pharmacotherapy 1:3, 515-535
CrossRef262
Peter E. Pool. (2000) Anomalies in the dosing of diltiazem. Clinical Cardiology 23:1, 18-23
CrossRef263
Morris J. Brown, Stephen Haydock. (2000) Pathoaetiology, Epidemiology and Diagnosis of Hypertension. Drugs 59:Supplement 2, 1-12
CrossRef264
Ravinder K. Wali, Matthew R. Weir. (1999) Hypertensive cardiovascular disease in African Americans. Current Hypertension Reports 1:6, 521-528
CrossRef265
Addison A. Taylor, Sarat Sunthornyothin. (1999) The case for combining angiotensinconverting enzyme inhibitors and calcium-channel blockers. Current Hypertension Reports 1:5, 446-453
CrossRef266
(1999) Racial Differences in the Outcome of Left Ventricular Dysfunction. New England Journal of Medicine 341:4, 287-288
Full Text267
James A. Schoenberger. (1999) Left ventricular hypertrophy: Unresolved issues. Current Hypertension Reports 1:4, 331-332
CrossRef268
Domenic A. Sica. (1999) Old antihypertensive agents-diuretics and β-Blockers: Do we know how and in whom they lower blood pressure?. Current Hypertension Reports 1:4, 296-304
CrossRef269
Dries, Daniel L., Exner, Derek V., Gersh, Bernard J., Cooper, Howard A., Carson, Peter E., Domanski, Michael J., . (1999) Racial Differences in the Outcome of Left Ventricular Dysfunction. New England Journal of Medicine 340:8, 609-616
Full Text270
Fabrizio Benedetti, Martina Amanzio, Sergio Baldi, Caterina Casadio, Giuliano Maggi. (1999) Inducing placebo respiratory depressant responses in humans via opioid receptors. European Journal of Neuroscience 11:2, 625-631
CrossRef271
Suzanne Oparil. (1999) Long-Term Morbidity and Mortality Trials with Amlodipine. Journal of Cardiovascular Pharmacology 33, S1-S6
CrossRef272
Lawrence E. Ramsay. (1999) Thiazide Diuretics in Hypertension. Clinical and Experimental Hypertension 21:5-6, 805-814
CrossRef273
Zdenka Pausova, Johanne Tremblay, Pavel Hamet. (1999) Gene-environment interactions in hypertension. Current Hypertension Reports 1:1, 42-50
CrossRef274
Peter S. Sever. (1999) α-Blockers in Hypertension. Current Medical Research and Opinion 15:2, 95-103
CrossRef275
B. Levine. (1999) Effect of Eprosartan and Enalapril in the Treatment of Black Hypertensive Patients: Subgroup Analysis of a 26-week, Double-blind, Multicentre Study. Current Medical Research and Opinion 15:1, 25-32
CrossRef276
Anna F. Dominiczak, James S. Clark, Baxter Jeffs, Niall H. Anderson, Cervantes D. Negrin, Wai K. Lee, M Julia Brosnan. (1998) Genetics of experimental hypertension. Journal of Hypertension 16:Supplement, 1859-1869
CrossRef277
D. Gorin. (1998) Effet iatrogène des médicaments à visée cardiovasculaire sur la fonction sexuelle érectile de l'homme. Andrologie 8:4, 391-404
CrossRef278
Gainer, James V., Morrow, Jason D., Loveland, AngelaKing, Debbie J., Brown, Nancy J., . (1998) Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive Subjects. New England Journal of Medicine 339:18, 1285-1292
Full Text279
Karri H. Helin, Ilkka Tikkanen, Johan E. von Knorring, Mauri J. Lepäntalo, B Kristian Liewendahl, Leena S. Laasonen, Frej Y. Fyhrquist, Tuula Tikkanen. (1998) Screening for renovascular hypertension in a population with relatively low prevalence. Journal of Hypertension 16:10, 1523-1529
CrossRef280
Gottlieb, Stephen S., McCarter, Robert J., Vogel, Robert A., . (1998) Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction. New England Journal of Medicine 339:8, 489-497
Full Text281
RI Marshall, PM Bartold. (1998) Medication induced gingival overgrowth. Oral Diseases 4:2, 130-151
CrossRef282
Alan H Gradman, Neal R Cutler, Pamela J Davis, John A Robbins, Robert J Weiss, Barry C Wood, Eric L Michelson. (1998) Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension. Clinical Therapeutics 20:3, 527-538
CrossRef283
Cynthia D Mulrow, Joseph Lau, John Cornell, M Brand, Cynthia D Mulrow. 1998. Pharmacotherapy for hypertension in the elderly. .
CrossRef284
Narayan, Man IN'T Veld. (1998) Clinical pharmacology of modern antihypertensive agents and their interaction with alpha-adrenoceptor antagonists. BJU International 81:S1, 6-16
CrossRef285
P. Sever. (1998) The Heterogeneity of Hypertension: Why Doesn't Every Patient Respond to Every Antihypertensive Drug?. Journal of Cardiovascular Pharmacology 31, S1-S4
CrossRef286
Fred E. Karch, Robert Pordy, Joan Ryder Benz, Albert Carr, N.Martin Lunde, Thomas Marbury, James N. Tarro. (1997) Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Clinical Therapeutics 19:6, 1368-1378
CrossRef287
Joel M. Neutel, David H.G. Smith, William H. Frishman. (1997) Optimization of antihypertensive therapy with a novel, extended-release formulation of diltiazem: results of a practice-based clinical study. Clinical Therapeutics 19:6, 1379-1393
CrossRef288
Edward D. Freis. (1997) CURRENT STATUS OF DIURETICS, β-BLOCKERS, α-BLOCKERS, AND α-β–BLOCKERS IN THE TREATMENT OF HYPERTENSION. Medical Clinics of North America 81:6, 1305-1317
CrossRef289
Ray W. Gifford. (1997) ANTIHYPERTENSIVE THERAPY. Medical Clinics of North America 81:6, 1319-1333
CrossRef290
Franz H. Messerli. (1997) HYPERTENSION IN SPECIAL POPULATIONS. Medical Clinics of North America 81:6, 1335-1345
CrossRef291
CC SZETO, SF LUI, AYM WANG, PKT LI, KN LAI. (1997) Factors affecting the therapeutic response of enalapril in treatment of post transplant erythrocytosis. Nephrology 3:4, 569-571
CrossRef292
Flávio Danni Fuchs, Miguel Gus, Wilson Dozza Moreira, Leila Beltrami Moreira, Renan Stoll Moraes, Guido Aranha Rosito, Artur Sorucco, Paulo Atanázio, Roberto Machado. (1997) Blood pressure effects of antihypertensive drugs and changes in lifestyle in a Brazilian hypertensive cohort. Journal of Hypertension 15:7, 783-792
CrossRef293
Barry M. Massie, Steven G Chrysant, Adesh Jain, Matthew Weir, Robert Weiss, Isaac Kobrin. (1997) Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. Clinical Cardiology 20:6, 562-568
CrossRef294
Marvin Moser. (1997) Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists and Calcium Channel Blocking Agents: A Review of Potential Benefits and Possible Adverse Reactions. Journal of the American College of Cardiology 29:7, 1414-1421
CrossRef295
Helen C. Mitchell, Ronald D. Smith, Ralph E. Cutler, Domenic Sica, John Videen, Sally Thompsen-Bell, Kim Jones, Carolyn Bradley-Guidry, Robert D. Toto. (1997) Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: A prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency. American Journal of Kidney Diseases 29:6, 897-906
CrossRef296
Mahboob Rahman, Janice G. Douglas, Jackson T. Wright. (1997) PATHOPHYSIOLOGY AND TREATMENT IMPLICATIONS OF HYPERTENSION IN THE AFRICAN-AMERICAN POPULATION. Endocrinology & Metabolism Clinics of North America 26:1, 125-144
CrossRef297
George S. Stergiou, John S. Malakos, Apostolos D. Achimastos, Theodore D. Mountokalakis. (1997) Additive Hypotensive Effect of a Dihydropyridine Calcium Antagonist to That Produced by a Thiazide Diuretic: A Double-Blind Placebo-Controlled Crossover Trial with Ambulatory Blood Pressure Monitoring. Journal of Cardiovascular Pharmacology 29:3, 412-416
CrossRef298
James E. Bailey, Marilyn D. Lee, Grant W. Somes, Robin L Graham. (1996) Risk factors for antihypertensive medication refill failure by patients under Medicaid managed care. Clinical Therapeutics 18:6, 1252-1262
CrossRef299
William J. Elliott. (1996) Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clinical Pharmacology & Therapeutics 60:5, 582-588
CrossRef300
JIS ROBERTSON. (1996) Critical review of treatment trials in hypertension. Nephrology 2:s1, s66-s71
CrossRef301
Lionel H. Opie. (1996) Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease. Cardiovascular Drugs and Therapy 10:4, 455-461
CrossRef302
Norman M. Kaplan. (1996) The CARE study: a postmarketing evaluation of ramipril in 11,100 patients. Clinical Therapeutics 18:4, 658-670
CrossRef303
Nancy J. Brown, Wayne A. Ray, Mary Snowden, Marie R. Griffin. (1996) Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema*. Clinical Pharmacology & Therapeutics 60:1, 8-13
CrossRef304
P. Smits. (1996) Role of potassium channels in the modulation of insulin release. Diabetologia 39:7, 865-867
CrossRef305
Charanjit Kapoor, Clement Singarajah, Haider Zafar, Kwabena O. Adubofour, Bruce Takahashi, Zoltan Vajo, William D. Dachman. (1996) Impaired β2-adrenergic agonist–induced venodilation in Indians of Asian origin*. Clinical Pharmacology & Therapeutics 59:5, 569-576
CrossRef306
Marvin Moser, Patricia R. Hebert. (1996) Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. Journal of the American College of Cardiology 27:5, 1214-1218
CrossRef307
MARK E. COWEN, MARY BANNISTER, RICHARD SHELLENBERGER, ROBERT TILDEN. (1996) A Guide for Planning Community-Oriented Health Care. Medical Care 34:3, 264-279
CrossRef308
Peter Trenkwalder, Michael Plaschke, Richard Aulehner, Helmut Lydtin. (1996) Felodipine or Hydrochlorothiazide/Triamterene for Treatment of Hypertension in the Elderly: Effects on Blood Pressure, Hypertensive Heart Disease, Metabolic and Hormonal Parameters. Blood Pressure 5:3, 154-163
CrossRef309
Paul K Whelton, Jeff D. Williamson, Gail T. Louis, Barry R. Davis, Jeffrey A. Cutler. (1996) Experimental Approaches to Determining the Choice of First-Step Therapy for Patients with Hypertension. Clinical and Experimental Hypertension 18:3-4, 569-579
CrossRef310
David A. Katzman, Benjamin Littenberg. (1995) Choosing antihypertensive therapy. Journal of General Internal Medicine 10:12, 700-702
CrossRef311
Terrence D. Ruddy, James M. Wright, Daniel Savard, S. Paul Handa, Arun Chockalingam, Lloyd Fischer, Andr
P. Boulet, . (1995) 24 hour blood pressure control with once-daily versus twice-daily formulations of diltiazem. Cardiovascular Drugs and Therapy 9:6, 799-807
CrossRef312
Timothy W. Odell, Martin C. Gregory. (1995) Cost of hypertension treatment. Journal of General Internal Medicine 10:12, 686-688
CrossRef313
N KAPLAN. (1995) Combination therapy for systemic hypertension. The American Journal of Cardiology 76:8, 595-597
CrossRef314
Terrence David Ruddy, James M. Wright, Daniel Savard, S. Paul Handa, Arun Chockalingam, Andr
CrossRef315
Lee Goldman. (1995) Internal medicine update. Journal of General Internal Medicine 10:6, 331-341
CrossRef316
Kevin M. Sowinski, Brad S. Burlew, Julie A. Johnson. (1995) Racial differences in sensitivity to the negative chronotropic effects of propranolol in healthy men*. Clinical Pharmacology & Therapeutics 57:6, 678-683
CrossRef317
Norman M. Kaplan, M.D. (1995) HYPERTENSION IN THE ELDERLY. Annual Review of Medicine 46:1, 27-35
CrossRef318
John S. Gottdiener, Domenic J. Reda, Barry J. Materson, Barry M. Massie, Alpo Notargiacomo, Robert J. Hamburger, David W. Williams, William G. Henderson. (1994) Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. Journal of the American College of Cardiology 24:6, 1492-1498
CrossRef319
Helen C. Noel, Judith S. Dempster. (1994) Essential Hypertension: Evaluation and Treatment. Journal of the American Academy of Nurse Practitioners 6:9, 421-435
CrossRef320
N.M. Kaplan. (1994) Ethnic aspects of hypertension. The Lancet 344:8920, 450-452
CrossRef321
N.E Bennet. (1994) Hypertension in the elderly. The Lancet 344:8920, 447-450
CrossRef322
Materson, Barry J., , Reda, Domenic J., . (1994) Correction: Single-Drug Therapy for Hypertension in Men. New England Journal of Medicine 330:23, 1689-1689
Full Text323
A. J. Jounela, M. Lilja, J. Lumme, C. Mörlin, A. Hoyem, T. Wessel-Aas, N. J. Borrild. (1994) Relation Between Low Dose of Hydrochlorothiazide, Antihypertensive Effect and Adverse Effects. Blood Pressure 3:4, 231-235
CrossRef324
Daniel W. Jones, Charles D. Sands. (1994) Lack of Effect of Hydrocholorthiazide on Total Cholesterol. Clinical and Experimental Hypertension 16:5, 675-689
CrossRef325
(1993) Single-Drug Therapy for Hypertension in Men. New England Journal of Medicine 329:14, 1043-1045
Full Text326
Oparil, Suzanne, . (1993) Antihypertensive Therapy -- Efficacy and Quality of Life. New England Journal of Medicine 328:13, 959-961
Full Text327
Thomas Hedner. (1993) The Nordic Diltiazem Study (NORDIL). A Prospective Intervention Trial of of Calcium Antagonist Therapy in Hypertension. Blood Pressure 2:4, 312-321
CrossRef
- Letters
